Date: 2012-04-16
Type of information:
phase: 2
Announcement: results
Company: Aicuris (Germany)
Product: AIC316
Action
mechanism: AIC316 is an specific inhibitor of herpes simplex virus (HSV) addressing a novel target (the viral helicase-primase complex). It also stems from a novel chemical class (thiazolylamides). AIC316 is active against both labial and genital herpes virus strains.
Based on this new mode of action, AIC316 does not require activation by viral thymidine kinase and therefore, is active – and protective – in uninfected cells. Similarly, due to its different mode of action, AIC316 also retains full activity against viruses that are resistant to marketed drugs. The favorably long plasma half-life of AIC316 on the one hand protects cells for extended periods of time against infection by the virus, on the other hand it is offers very convenient dosing regimens for patients (expected: one pill per episode for treatment of a herpes episode, once weekly treatment for suppression of genital herpes).
Disease: genital herpes
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: AiCuris has announced that in depth analysis of data from the AIC316 Phase 2 trial in patients with genital herpes will be disclosed at several international meetings. This information adds to the efficacy data meeting the primary endpoint of the trial which have already been announced (See http://biopharmanalyses.fr/clinical-trails/?pageid=307 and http://biopharmanalyses.fr/clinical-trails/?pageid=220).
AiCuris project leader Dr. Alexander Birkmann will present the data at the International Conference on Antiviral Research (ICAR) meeting in Sapporo, Japan, on 19th April 2012. Furthermore, Professor Helga Rübsamen-Schaeff, CEO of AiCuris, will give an invited talk on AIC316 discussing this topic at the International Herpesvirus Workshop in Calgary, Canada, 4th-9th August 2012.
